These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21781307)

  • 21. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
    Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
    Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.
    Liu SH; Shen CC; Yi YC; Tsai JJ; Wang CC; Chueh JT; Lin KL; Lee TC; Pan HC; Sheu ML
    Br J Pharmacol; 2010 Aug; 160(8):1963-72. PubMed ID: 20649594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3'-hydroxy-3,4,5,4'-tetramethoxystilbene, the metabolite of resveratrol analogue DMU-212, inhibits ovarian cancer cell growth in vitro and in a mice xenograft model.
    Piotrowska-Kempisty H; Ruciński M; Borys S; Kucińska M; Kaczmarek M; Zawierucha P; Wierzchowski M; Łażewski D; Murias M; Jodynis-Liebert J
    Sci Rep; 2016 Sep; 6():32627. PubMed ID: 27585955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
    Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
    Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
    Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
    Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients.
    Hua TNM; Oh J; Kim S; Antonio JM; Vo VTA; Om J; Choi JW; Kim JY; Jung CW; Park MJ; Jeong Y
    Exp Mol Med; 2020 Apr; 52(4):629-642. PubMed ID: 32280134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
    Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
    Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
    Al-Alem L; Southard RC; Kilgore MW; Curry TE
    PLoS One; 2011 Jan; 6(1):e16179. PubMed ID: 21283708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.
    Xiong X; Wang L; Ye Y; Fu L; Chen M; Wang Q; Liu M; Tang J; Dai B; Shen J; Mei C
    Invest New Drugs; 2010 Aug; 28(4):472-81. PubMed ID: 19533021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
    Morgado M; Carson DD
    J Cell Biochem; 2017 Jan; 118(1):163-171. PubMed ID: 27292441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
    Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
    Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined PPARγ Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors.
    Leung DTH; Nguyen T; Oliver EM; Matti J; Alexiadis M; Silke J; Jobling TW; Fuller PJ; Chu S
    Mol Cancer Ther; 2019 Feb; 18(2):364-375. PubMed ID: 30530769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.
    Song J; Shih IeM; Chan DW; Zhang Z
    Neoplasia; 2009 Jun; 11(6):605-14, 1 p following 614. PubMed ID: 19484149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.
    Wiiger MT; Bideli H; Fodstad O; Flatmark K; Andersson Y
    J Ovarian Res; 2014 Feb; 7():23. PubMed ID: 24528603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
    J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
    Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.
    Dobbin ZC; Katre AA; Steg AD; Erickson BK; Shah MM; Alvarez RD; Conner MG; Schneider D; Chen D; Landen CN
    Oncotarget; 2014 Sep; 5(18):8750-64. PubMed ID: 25209969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Influence of rosiglitazone and all-trans-retinoic acid on angiogenesis and growth of myeloma xenograft in nude mice].
    Huang HW; Chen P; Li BZ; Fu JX; Li J; Zhang XH; Liu R; Fan YY; Zhang H; Chow HC; Leung AY; Liang R
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):652-7. PubMed ID: 23159076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.